Four months after receiving a complete response letter from the U.S. FDA for tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis, Sanofi SA received a positive opinion ...

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, ...

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals Inc.’s DB-OTO, an AAV-mediated gene ...

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing ...

Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to ...

Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a ...

A modified version of CRISPR-Cas9 has enabled, for the first time, the efficient integration of a large transgene capable of ...

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not ...

With rezpegaldesleukin (rezpeg) phase IIb data in alopecia areata holding strong over time, backers of Nektar Therapeutics ...

Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April ...

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically significant results do not read across to ...

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a surge in investment in companies ...